NASDAQ:ATXI Avenue Therapeutics (ATXI) Stock Price, News & Analysis → Must-See: Elon’s New Invention is Absolutely Insane (From InvestorPlace) (Ad) Free ATXI Stock Alerts $3.64 -0.07 (-1.89%) (As of 11:59 AM ET) Add Compare Share Share Today's Range$3.62▼$3.8950-Day Range$3.63▼$12.0052-Week Range$3.52▼$93.75Volume23,098 shsAverage Volume77,997 shsMarket Capitalization$2.15 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaSustainability Get Avenue Therapeutics alerts: Email Address Ad Colonial MetalsWARNING about the death of the U.S. dollar…Where do you turn during times of economic uncertainty? Many elites trust storing their wealth in gold (which has historically boomed when the dollar’s value has plummeted!)Get Colonial Metals' new Precious Metals Investment Guide. About Avenue Therapeutics Stock (NASDAQ:ATXI)Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.Read More ATXI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATXI Stock News HeadlinesMay 16, 2024 | globenewswire.comAvenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)May 15, 2024 | investorplace.comATXI Stock Earnings: Avenue Therapeutics Misses EPS for Q1 2024May 15, 2024 | globenewswire.comAvenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsMay 3, 2024 | msn.comMultiple lane closures coming to Capitol Avenue in downtown IndyMay 3, 2024 | msn.comPickup truck hits girl, flees the scene on Lamar AvenueMay 2, 2024 | msn.com2 people in critical condition after shooting on Arlington Avenue in ChattanoogaMay 2, 2024 | msn.comCrash with injuries, entrapment reported on Hamilton Avenue in Springfield TownshipMay 2, 2024 | msn.comMelrose Avenue record shop celebrates vinyl albums, takes music collectors on a journey through timeMay 2, 2024 | msn.comBrickell Avenue is the priciest commercial street in MiamiMay 2, 2024 | msn.comMilwaukee's National Avenue will see its auto lanes cut. Other safety changes are comingMay 2, 2024 | msn.comCity Avenue in Lower Merion set to triple its apartment count, transforming the office and retail hubMay 2, 2024 | msn.comGirl critically injured in hit-and-run on Lamar AvenueMay 2, 2024 | msn.com'It's wholesome': Houston Avenue church to host gospel rap concert to spread love in communityMay 2, 2024 | msn.comMeeting held about 'rightsizing' Penn Avenue in the Strip DistrictMay 1, 2024 | msn.comPittsburgh International Jazz Festival brings free concerts to Liberty AvenueMay 1, 2024 | msn.comMan found shot multiple times along Cleveland AvenueApril 30, 2024 | msn.comSilver Diner Opening In The Avenue At White Marsh With Reimagined MenuApril 30, 2024 | yahoo.comCar crashes into Flying Burrito on College Avenue in FayettevilleApril 30, 2024 | msn.comWhy one block of Acero Avenue in Pueblo is being converted to a one-way streetApril 30, 2024 | startribune.comSt. Paul restores Rondo Avenue name to city streetApril 30, 2024 | msn.comIWC Schaffhausen Fetes New Boutique for Madison Avenue Watch WeekApril 30, 2024 | yahoo.comMadison Avenue Watch Week Returns With Breitling, Ralph Lauren, Apple and Others, After Pandemic HiatusApril 30, 2024 | msn.com2 Oak Lawn Men ID’d In Deadly Crash At 87th Street and Cicero AvenueApril 29, 2024 | msn.comReported crash with injuries in Reading on East Columbia AvenueApril 29, 2024 | msn.comPart of Starbuck Avenue to be closed on MondaySee More Headlines Receive ATXI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avenue Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today5/23/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ATXI CUSIPN/A CIK1644963 Webwww.avenuetx.com Phone(781) 652-4500FaxN/AEmployees3Year Founded2015Profitability EPS (Most Recent Fiscal Year)($7.8817) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,380,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-391.98% Debt Debt-to-Equity RatioN/A Current Ratio2.34 Quick Ratio2.34 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.22 per share Price / Book1.15Miscellaneous Outstanding Shares590,000Free Float578,000Market Cap$2.19 million OptionableNot Optionable Beta-0.09 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Alexandra MacLean M.D. (Age 56)CEO & Director Comp: $413.2kMr. David Jin (Age 33)Interim CFO, COO & Corporate Secretary Dr. Lindsay Allan Rosenwald (Age 69)Executive Director Dr. Xiaoqin Lu M.D. (Age 49)Consultant Comp: $1.05MDr. Scott A. Reines M.D. (Age 77)Ph.D., Interim Chief Medical Officer Comp: $69.12kMr. Srinivas Subramanian (Age 53)Executive Vice President More ExecutivesKey CompetitorsSalarius PharmaceuticalsNASDAQ:SLRXLucy Scientific DiscoveryNASDAQ:LSDICohBarNASDAQ:CWBRNotable LabsNASDAQ:NTBLAltamira TherapeuticsNASDAQ:CYTOView All CompetitorsInsidersFortress Biotech, Inc.Bought 5,578 shares on 9/8/2023Total: $301,212.00 ($54.00/share)Lindsay A Md RosenwaldBought 4,649 shares on 9/8/2023Total: $251,046.00 ($54.00/share)View All Insider Transactions ATXI Stock Analysis - Frequently Asked Questions Should I buy or sell Avenue Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avenue Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATXI shares. View ATXI analyst ratings or view top-rated stocks. How have ATXI shares performed in 2024? Avenue Therapeutics' stock was trading at $12.0750 on January 1st, 2024. Since then, ATXI stock has decreased by 69.9% and is now trading at $3.64. View the best growth stocks for 2024 here. When is Avenue Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our ATXI earnings forecast. How were Avenue Therapeutics' earnings last quarter? Avenue Therapeutics, Inc. (NASDAQ:ATXI) released its earnings results on Monday, March, 18th. The company reported $42.00 EPS for the quarter. When did Avenue Therapeutics' stock split? Avenue Therapeutics shares reverse split on Friday, April 26th 2024. The 1-75 reverse split was announced on Friday, April 26th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. What other stocks do shareholders of Avenue Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avenue Therapeutics investors own include Gilead Sciences (GILD), AbbVie (ABBV), Fulcrum Therapeutics (FULC), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Allena Pharmaceuticals (ALNA), Actinium Pharmaceuticals (ATNM), CymaBay Therapeutics (CBAY), CytomX Therapeutics (CTMX) and Spero Therapeutics (SPRO). When did Avenue Therapeutics IPO? Avenue Therapeutics (ATXI) raised $30 million in an initial public offering on Tuesday, June 27th 2017. The company issued 5,000,000 shares at a price of $5.00-$7.00 per share. Oppenheimer acted as the underwriter for the IPO and National Securities Corp. was co-manager. How do I buy shares of Avenue Therapeutics? Shares of ATXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ATXI) was last updated on 5/23/2024 by MarketBeat.com Staff From Our PartnersDividend-like income from non-dividend stocksUnstoppable ProsperityTop 5 Tech Stocks to Buy for 2024Daily Market AlertsThe most important AI company you've never heard ofManward PressBill Gates is all about this tiny $2 stockTimothy SykesTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaElon to Transform U.S. Economy? Porter & CompanyMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceWrite this ticker symbol down…StocksToTrade Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avenue Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.